Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.9% Following Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 2.9% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $8.03 and last traded at $8.11. 1,120,668 shares were traded during trading, a decline of 81% from the average session volume of 6,053,652 shares. The stock had previously closed at $8.35.

Specifically, COO Tina Marriott sold 6,000 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $8.13, for a total transaction of $48,780.00. Following the completion of the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $4,353,265.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the sale, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $4,353,265.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $9.32, for a total transaction of $139,800.00. Following the completion of the sale, the chief financial officer now owns 1,243,468 shares of the company’s stock, valued at approximately $11,589,121.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 202,235 shares of company stock valued at $1,654,400. 15.75% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have issued reports on RXRX shares. Needham & Company LLC restated a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th. KeyCorp dropped their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th.

Recursion Pharmaceuticals Stock Performance

The company has a fifty day moving average of $8.44 and a two-hundred day moving average of $9.51.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. During the same quarter last year, the firm earned ($0.34) earnings per share. The company’s revenue was up 14.0% on a year-over-year basis. Analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at approximately $26,000. National Bank of Canada FI lifted its position in shares of Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after acquiring an additional 1,500 shares during the period. First Horizon Advisors Inc. bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $47,000. GAMMA Investing LLC increased its position in shares of Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the period. Finally, Midwest Financial Group LLC bought a new position in shares of Recursion Pharmaceuticals in the second quarter worth $90,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.